 Connection
Marc Bonaca to Diabetes Mellitus
This is a "connection" page, showing publications Marc Bonaca has written about Diabetes Mellitus.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
2.101 |
|
|
|
-
Canonico ME, Hsia J, Cannon CP, Bonaca MP. Uptake of Newer Guideline-Directed Therapies in Heart?Failure Patients With Diabetes or Chronic Kidney Disease. JACC Heart Fail. 2022 12; 10(12):989-991.
Score: 0.476
-
Behan SA, Mulder H, Rockhold FW, Gutierrez JA, Baumgartner I, Katona BG, Mahaffey KW, Norgren L, Jones S, Bonaca MP. Impact of Polyvascular Disease and Diabetes on?Limb and Cardiovascular Risk in Peripheral Artery Disease. J Am Coll Cardiol. 2022 05 03; 79(17):1781-1783.
Score: 0.459
-
Govsyeyev N, Nehler MR, Low Wang CC, Kavanagh S, Hiatt WR, Long C, Jones WS, Fowkes FGR, Berger JS, Baumgartner I, Patel MR, Goodney PP, Beckman JA, Katona BG, Mahaffey KW, Blomster J, Norgren L, Bonaca MP. Etiology and outcomes of amputation in patients with peripheral artery disease in the EUCLID trial. J Vasc Surg. 2022 02; 75(2):660-670.e3.
Score: 0.440
-
Fowler XP, Eid MA, Barnes JA, Gladders B, Austin AM, Goodney EJ, Moore KO, Kearing S, Feinberg MW, Bonaca MP, Creager MA, Goodney PP. Trends of Concomitant Diabetes and Peripheral Artery Disease and Lower Extremity Amputation in US Medicare Patients, 2007 to 2019. Circ Cardiovasc Qual Outcomes. 2023 06; 16(6):e009531.
Score: 0.124
-
Austin AM, Ramkumar N, Gladders B, Barnes JA, Eid MA, Moore KO, Feinberg MW, Creager MA, Bonaca M, Goodney PP. Using a cohort study of diabetes and peripheral artery disease to compare logistic regression and machine learning via random forest modeling. BMC Med Res Methodol. 2022 11 23; 22(1):300.
Score: 0.119
-
Aday AW, Duncan MS, Patterson OV, DuVall SL, Alba PR, Alcorn CW, Tindle HA, Creager MA, Bonaca MP, Damrauer SM, Wells QS, Behroozian A, Beckman JA, Freiberg MS. Association of Sex and Race With Incident Peripheral Artery Disease Among Veterans With Normal Ankle-Brachial Indices. JAMA Netw Open. 2022 11 01; 5(11):e2240188.
Score: 0.119
-
McCoy MG, Jamaiyar A, Sausen G, Cheng HS, P?rez-Cremades D, Zhuang R, Chen J, Goodney PP, Creager MA, Sabatine MS, Bonaca MP, Feinberg MW. MicroRNA-375 repression of Kruppel-like factor 5 improves angiogenesis in diabetic critical limb ischemia. Angiogenesis. 2023 02; 26(1):107-127.
Score: 0.117
-
Thomas MR, Angiolillo DJ, Bonaca MP, Ajjan RA, Judge HM, Rollini F, Franchi F, Ahsan AJ, Bhatt DL, Kuder JF, Steg PG, Cohen M, Muthusamy R, Sabatine MS, Storey RF. Consistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes status. Thromb Haemost. 2017 05 03; 117(5):940-947.
Score: 0.080
-
Bhatt DL, Bonaca MP, Bansilal S, Angiolillo DJ, Cohen M, Storey RF, Im K, Murphy SA, Held P, Braunwald E, Sabatine MS, Steg PG. Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-TIMI 54. J Am Coll Cardiol. 2016 Jun 14; 67(23):2732-2740.
Score: 0.075
-
Cavender MA, Scirica BM, Bonaca MP, Angiolillo DJ, Dalby AJ, Dellborg M, Morais J, Murphy SA, Ophuis TO, Tendera M, Braunwald E, Morrow DA. Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-TIMI 50 trial. Circulation. 2015 Mar 24; 131(12):1047-53.
Score: 0.070
-
Mok Y, Ballew SH, Bash LD, Bhatt DL, Boden WE, Bonaca MP, Carrero JJ, Coresh J, D'Agostino RB, Elley CR, Fowkes FGR, Jee SH, Kovesdy CP, Mahaffey KW, Nadkarni G, Peterson ED, Sang Y, Matsushita K. International Validation of the Thrombolysis in Myocardial Infarction (TIMI) Risk Score for Secondary Prevention in Post-MI Patients: A Collaborative Analysis of the Chronic Kidney Disease Prognosis Consortium and the Risk Validation Scientific Committee. J Am Heart Assoc. 2018 07 07; 7(14).
Score: 0.022
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|